GSK's Covid antibody treatment works on Omicron mutations, finds study

The drugmaker in a statement said the tests done in-vitro against a pseudo-virus that recreates a synthesized version of omicron showed that sotrovimab, Glaxo’s antibody treatment, stands up to all mutations in the spike protein of the omicron variant and not just the key mutations

from mint - Science https://ift.tt/3EwEew3